TY - JOUR
T1 - Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression
T2 - A systematic review and network meta-analysis of phase 3 trials in Japan
AU - Kishi, Taro
AU - Yoshimura, Reiji
AU - Sakuma, Kenji
AU - Okuya, Makoto
AU - Iwata, Nakao
N1 - Funding Information:
This is a collaboration study with Sumitomo Dainippon Pharma Co., Ltd (Tokyo, Japan ?104-8356). We thank Sumitomo Dainippon Pharma Co., Ltd., for confirming the accuracy of data in unpublished lurasidone study (NCT01986101)5 and for their advice on this article.
Funding Information:
The present study was supported by the Grant‐in‐Aid for Scientific Research (C) (19K08082). The authors have declared that there are no conflicts of interest relating to the subject of this study. Interests from the past 3 years are as follows. Dr Kishi received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, Mochida, MSD, and Tanabe‐Mitsubishi (Yoshitomi); as well as research grants from the Japanese Ministry of Health, Labour and Welfare, Grant‐in‐Aid for Scientific Research (C), and Fujita Health University School of Medicine. Prof. Yoshimura has received speaker's honoraria from Dainippon Sumitomo, Eli Lilly, Otsuka, and Meiji. Dr Sakuma has received speaker's honoraria from Eisai, Kissei, Meiji, Otsuka, and Torii; and has received a Fujita Health University School of Medicine research grant, as well as a Grant‐in‐Aid for Young Scientists (B). Dr Okuya has received speaker's honoraria from Meiji. Dr Iwata received speaker's honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer; along with research grants from GlaxoSmithKline, Meiji, and Otsuka.
PY - 2020/12
Y1 - 2020/12
N2 - Aim: This systematic review and random-effect model, network meta-analysis of the phase 3 trials in Japan assessed the efficacy and safety profile of lurasidone compared with olanzapine and quetiapine extended-release (QUE-XR) for the treatment of bipolar depression. Methods: The study included double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with bipolar depression. Outcomes included response rate (primary), remission rate (secondary), improvement of Montgomery-Åsberg Depression Rating Scale (MADRS) total score, discontinuation rates, and incidence of individual adverse events. Results: Three studies were included (n = 1223). Lurasidone and olanzapine but not QUE-XR were superior to placebo in response rate [risk ratio (95% credible interval): lurasidone = 0.78 (0.66, 0.92); olanzapine = 0.84 (0.71, 0.99); QUE-XR = 0.87 (0.73, 1.03)]. Lurasidone, olanzapine and QUE-XR were superior to placebo in remission rate [lurasidone = 0.90 (0.83, 0.98); olanzapine = 0.87 (0.77, 0.99); QUE-XR = 0.84 (0.73, 0.98)] and the improvement of MADRS total score. There were not differences in discontinuation rates between each antipsychotic and placebo. Compared with placebo, lurasidone was higher incidence of akathisia, and increased body weight and blood prolactin level; olanzapine was higher incidence of somnolence and ≥7% weight gain, and increased body weight, blood total cholesterol level, blood LDL cholesterol level, and blood triglyceride levels; QUE-XR was higher incidence of extrapyramidal symptoms, akathisia, somnolence, dry mouth, constipation and ≥7% weight gain, and increased body weight, blood total cholesterol level, blood LDL cholesterol level, and blood triglyceride levels. Conclusions: Our results suggested although the efficacy of three SGAs was similar, there were the differences in the safety profile among the SGAs.
AB - Aim: This systematic review and random-effect model, network meta-analysis of the phase 3 trials in Japan assessed the efficacy and safety profile of lurasidone compared with olanzapine and quetiapine extended-release (QUE-XR) for the treatment of bipolar depression. Methods: The study included double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with bipolar depression. Outcomes included response rate (primary), remission rate (secondary), improvement of Montgomery-Åsberg Depression Rating Scale (MADRS) total score, discontinuation rates, and incidence of individual adverse events. Results: Three studies were included (n = 1223). Lurasidone and olanzapine but not QUE-XR were superior to placebo in response rate [risk ratio (95% credible interval): lurasidone = 0.78 (0.66, 0.92); olanzapine = 0.84 (0.71, 0.99); QUE-XR = 0.87 (0.73, 1.03)]. Lurasidone, olanzapine and QUE-XR were superior to placebo in remission rate [lurasidone = 0.90 (0.83, 0.98); olanzapine = 0.87 (0.77, 0.99); QUE-XR = 0.84 (0.73, 0.98)] and the improvement of MADRS total score. There were not differences in discontinuation rates between each antipsychotic and placebo. Compared with placebo, lurasidone was higher incidence of akathisia, and increased body weight and blood prolactin level; olanzapine was higher incidence of somnolence and ≥7% weight gain, and increased body weight, blood total cholesterol level, blood LDL cholesterol level, and blood triglyceride levels; QUE-XR was higher incidence of extrapyramidal symptoms, akathisia, somnolence, dry mouth, constipation and ≥7% weight gain, and increased body weight, blood total cholesterol level, blood LDL cholesterol level, and blood triglyceride levels. Conclusions: Our results suggested although the efficacy of three SGAs was similar, there were the differences in the safety profile among the SGAs.
UR - http://www.scopus.com/inward/record.url?scp=85090444045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090444045&partnerID=8YFLogxK
U2 - 10.1002/npr2.12137
DO - 10.1002/npr2.12137
M3 - Article
AN - SCOPUS:85090444045
VL - 40
SP - 417
EP - 422
JO - Neuropsychopharmacology Reports
JF - Neuropsychopharmacology Reports
SN - 1340-2544
IS - 4
ER -